Pathology Faculty Member

More information on...

  • Home
  • Training
  • Research
  • Clinical Services
  • Expert Consultation
  • Faculty
  • Contact Information:

    Anatomic Pathology
    H174 EUH
    Atlanta GA 30322
    404-712-8411 Phone

    For an expert Pathology consultation,
    or to send a specimen, call:

    1-404-712-5947


    Adeboye O Osunkoya, MD

    Genitourinary Pathology
    Surgical Pathology

    Associate Professor
    Pathology & Laboratory Medicine


    Pathology Faculty Photo

    Other Appointments/Positions

    Associate Professor of Urology, Emory University School of Medicine

    Director, Urologic / Genitourinary Pathology, Emory University School of Medicine

    Director, Pathology Grand Rounds / Distinguished Visiting Professorship Program, Emory University School of Medicine

    Director, Surgical Pathology Fellowship Program, Emory University School of Medicine


    Pathology Division(s):
    Anatomic Pathology


    Email Address:
    adeboye.osunkoya@emory.edu


    Education:

      MBBS University of Ibadan College of Medicine, Oyo State, Nigeria, - 1998

      Intern, University College Hospital, Ibadan, - 1999

      Research Fellow, Institute of Child Health, University College Hospital, Ibadan, - 2000

      Resident, Anatomic and Clinical Pathology, University College Hospital, Ibadan, 2000 - 2002

      Resident, Anatomic and Clinical Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 2002 - 2004

      Chief Resident, Anatomic and Clinical Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 2004 - 2006

      Clinical and Research Fellow, Division of Genitourinary Pathology, The Johns Hopkins Hospital, Baltimore, MD, 2006 - 2007



    Research Interests:

    - Urologic/Genitourinary Pathology
    My research interests are mainly in the field of Urologic/Genitourinary pathology. Prostate: We have studied the largest series to date of mucinous prostate cancer, colon cancer with prostatic involvement, primary mucin-producing urothelial-type adenocarcinoma of prostate and prostate cancer with aberrant p63 expression. We have also analyzed the expression of MUC-2, VEGF and ZEB-1 in prostate cancer, and have utilized multiplexed quantum dots in molecular mapping of tumor heterogeneity on tissue specimens of patients with prostate cancer. Kidney: We have analyzed diagnostic biomarkers for renal cell carcinoma (RCC), based on a selection utilizing novel bioinformatics systems for microarray data analysis. We have also studied the utility of Claudin 7 and 8 in the distinction between renal oncocytoma and chromophobe RCC, and the expression of PAX-2 and CA-IX in RCC. In addition, we are one of the first groups to confirm the distinction between tubulocystic carcinoma and collecting duct carcinoma of the kidney at the molecular level, based on comparison of gene expression profiles. Urinary Bladder: We are one of the first groups to describe a unique variant of bladder cancer (urothelial carcinoma with villoglandular differentiation). We have also analyzed one of the largest series to date of plasmacytoid urothelial carcinoma and smooth muscle neoplasms of the urinary bladder. Testis: We have analyzed the significance of rete testis involvement by malignant germ cell neoplasia and/or intratubular germ cell neoplasia. We have also studied lymphoid neoplasms of the urinary tract and male genital organs.



    Clinical Focus:

    My clinical focus is in Surgical Pathology with major emphasis on Urologic/Genitourinary Pathology. I sign out general Surgical Pathology cases and frozen sections at both Emory University Hospital and the Veterans Affairs Medical Center. I also sign out autopsies, gynecologic and non-gynecologic cytology (including urine cytology) cases at the latter. I handle in house Urologic/Genitourinary Pathology consultation cases from Emory University Hospital, Veterans Affairs Medical Center, Emory Midtown Hospital, Grady Hospital and Children's Healthcare of Atlanta at Egleston and Scottish Rite. In addition, I offer expert consultation from outside institutions in the area of Urologic/Genitourinary Pathology (please see separate website link: http://pathology.emory.edu/ExpertConsultation_Forms.html). I have a secondary appointment in the department of Urology and I am active in their tumor boards at both the Emory University Hospital and the Veterans Affairs Medical Center.


    Honors / Awards:

    Chair, Excellence in Urological Pathology Resident/Fellow Research Award Committee, International Society of Urological Pathology, 2013-

    Member, Education Committee, United States and Canadian Academy of Pathology, 2012-

    Section Editor, Urologic Pathology, Archives of Pathology and Laboratory Medicine, 2012-

    Member, Editorial Board, Human Pathology, 2012-

    Member, Editorial Board, Pathology, 2012-

    Member, Abstract Review Board, College of American Pathologists, 2012-

    Invited Speaker, 20th Anniversary of the International Society of Urological Pathology, Vancouver, Canada, 2012

    Member, Stowell-Orbison Award Committee, United States and Canadian Academy of Pathology, 2011-2012

    Visiting Professor, Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 2011

    Member, Abstract Review Board, United States and Canadian Academy of Pathology, 2011

    Member, Editorial Board, International Journal of Clinical and Experimental Pathology, 2010-

    Invited Scholar, Emory University School of Medicine, Junior Faculty Development Course, 2010

    Benjamin Castleman Award, United States and Canadian Academy of Pathology, 2010

    NCI Prostate Specialized Programs of Research Excellence (SPORE) Grants Program, Ad Hoc Reviewer, 2010

    Golden Apple Award for Excellence in Resident Education. Department of Pathology, Emory University School of Medicine, Atlanta, GA, 2009-2010

    Young Investigator Award in Clinical Research, Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD, 2007

    Perry Lambird Award, Outstanding Resident in Clinical Pathology, University of Oklahoma Health Sciences Center, OK, 2006

    Parker-Heartland Award, Outstanding Resident in Anatomic Pathology, University of Oklahoma Health Sciences Center,OK, 2005

    Donald West King Fellow, Gastrointestinal Pathology Division, Armed Forces Institute of Pathology, Washington, DC, 2005

    Chief Resident, Anatomic and Clinical Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 2004-2006

    Member, Residents Council, University of Oklahoma Health Sciences Center, OK, 2003/2004

    Nancy K. Hall Award for Most Outstanding First Year Resident, Department of Pathology, University of Oklahoma Health Sciences Center, OK, 2003

    Specialty Boards:

    Aug 2006  Anatomic and Clinical Pathology


    Selected Publications:

    Published and Accepted Research Articles -

    Johnson H, Zhou M, Osunkoya AO. ERG expression in mucinous prostatic adenocarcinoma and prostatic adenocarcinoma with mucinous features: comparison with conventional prostatic adenocarcinoma. Hum Pathol. 2013;44(10):2241-6.


    Gooden C, Nieh PT, Osunkoya AO. Histologic findings on prostate needle core biopsies following cryotherapy as monotherapy for prostatic adenocarcinoma. Hum Pathol. 2013;44(5):867-72.


    Lauer SR, Zhou M, Master VA, Osunkoya AO. Chromophobe renal cell carcinoma with sarcomatoid differentiation: a clinicopathologic study of 14 cases. Anal Quant Cytol Histol. 2013;35(2):77-84.


    Ehsani L, Seth R, Bacopulos S, Seth A, Osunkoya AO. BCA2 is differentially expressed in renal oncocytoma: an analysis of 158 renal neoplasms. Tumour Biol. 2013;34(2):787-91.


    Ehsani L, Osunkoya AO. Schistosomiasis of the prostate: a case report. Anal Quant Cytol Histol. 2013;35(3):178-80.


    Schelling LA, Williamson SR, Zhang S, Yao JL, Wang M, Huang J, Montironi R, Lopez-Beltran A, Emerson RE, Idrees MT, Osunkoya AO, Man YG, Maclennan GT, Baldridge LA, Compérat E, Cheng L. Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry. Hum Pathol. 2013;44(10):2227-33.


    Arnold RS, Sun Q, Sun CQ, Richards JC, O'Hearn S, Osunkoya AO, Wallace DC, Petros JA. An inherited heteroplasmic mutation in mitochondrial gene COI in a patient with prostate cancer alters reactive oxygen, reactive nitrogen and proliferation. Biomed Res Int. 2013;2013:239257.


    Schuster DM, Taleghani PA, Nieh PT, Master VA, Amzat R, Savir-Baruch B, Halkar RK, Fox T, Osunkoya AO, Moreno CS, Nye JA, Yu W, Fei B, Wang Z, Chen Z, Goodman MM. Characterization of primary prostate carcinoma by anti-1-amino-2-[(18)F] -fluorocyclobutane-1-carboxylic acid (anti-3-[(18)F] FACBC) uptake. Am J Nucl Med Mol Imaging. 2013;3(1):85-96.


    Zhang S, Wang X, Iqbal S, Wang Y, Osunkoya AO, Chen Z, Chen Z, Shin DM, Yuan H, Wang YA, Zhau HE, Chung LW, Ritenour C, Kucuk O, Wu D. Epidermal growth factor promotes protein degradation of epithelial protein lost in neoplasm (EPLIN), a putative metastasis suppressor, during epithelial-mesenchymal transition. J Biol Chem. 2013;288(3):1469-79.


    Amzat R, Taleghani P, Miller DL, Beitler JJ, Bellamy LM, Nye JA, Yu W, Savir-Baruch B, Osunkoya AO, Chen Z, Auffermann WF, Goodman MM, Schuster DM. Pilot study of the utility of the synthetic PET amino-acid radiotracer anti-1-amino-3-[(18)F]fluorocyclobutane-1-carboxylic acid for the noninvasive imaging of pulmonary lesions. Mol Imaging Biol. 2013;15(5):633-43.


    Srigley JR, Delahunt B, Eble JN, Egevad L, Epstein JI, Grignon D, Hes O, Moch H, Montironi R, Tickoo SK, Zhou M, Argani P; ISUP Renal Tumor Panel. The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol. 2013;37(10):1469-89.


    Delahunt B, Cheville JC, Martignoni G, Humphrey PA, Magi-Galluzzi C, McKenney J, Egevad L, Algaba F, Moch H, Grignon DJ, Montironi R, Srigley JR; Members of the ISUP Renal Tumor Panel. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol. 2013;37(10):1490-504.


    Trpkov K, Grignon DJ, Bonsib SM, Amin MB, Billis A, Lopez-Beltran A, Samaratunga H, Tamboli P, Delahunt B, Egevad L, Montironi R, Srigley JR; members of the ISUP Renal Tumor Panel. Handling and staging of renal cell carcinoma: the International Society of Urological Pathology Consensus (ISUP) conference recommendations. Am J Surg Pathol. 2013;37(10):1505-17.


    Tan PH, Cheng L, Rioux-Leclercq N, Merino MJ, Netto G, Reuter VE, Shen SS, Grignon DJ, Montironi R, Egevad L, Srigley JR, Delahunt B, Moch H; ISUP Renal Tumor Panel. Renal tumors: diagnostic and prognostic biomarkers. Am J Surg Pathol. 2013;37(10):1518-31.


    Derosa AD, Baldie KG, Osunkoya AO, Pattaras JG. Metastatic retroperitoneal hemangiopericytoma. Can J Urol. 2013;20(6):7070-2.


    Shrewsberry AB, Sica GL, Osunkoya AO, Canter DJ. Epithelioid PEComa (epithelioid angiomyolipoma) of the kidney: a rare tumor subtype for patients presenting with an enhancing renal mass. Can J Urol. 2013;20(1):6643-5.


    Osunkoya AO. Update on prostate pathology. Pathology. 2012;44(5):391-406.


    Lee MJ, Vogt AP, Hsiao W, Osunkoya AO. CDX-2 expression in malignant germ cell tumors of the testes, intratubular germ cell neoplasia, and normal seminiferous tubules. Tumour Biol. 2012;33(6):2185-8.  


    Gupta R, Billis A, Shah RB, Moch H, Osunkoya AO, Jochum W, Hes O, Bacchi CE, de Castro MG, Hansel DE, Zhou M, Vankalakunti M, Salles PG, Cabrera RA, Gown AM, Amin MB. Carcinoma of the Collecting Ducts of Bellini and Renal Medullary Carcinoma: Clinicopathologic Analysis of 52 Cases of Rare Aggressive Subtypes of Renal Cell Carcinoma With a Focus on Their Interrelationship. Am J Surg Pathol. 2012;36(9):1265-1278.


    Akbari H, Halig LV, Schuster DM, Osunkoya A, Master V, Nieh PT, Chen GZ, Fei B. Hyperspectral imaging and quantitative analysis for prostate cancer detection. J Biomed Opt. 2012;17(7):076005.


    Watts KE, Montironi R, Mazzucchelli R, van der Kwast T, Osunkoya AO, Stephenson AJ, Hansel DE. Clinicopathologic Characteristics of 23 Cases of Invasive Low-grade Papillary Urothelial Carcinoma. Urology. 2012;80(2):361-6.


    Chen H, Sun Y, Wu C, Magyar CE, Li X, Cheng L, Yao JL, Shen S, Osunkoya AO, Liang C, Huang J. Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway. Endocr Relat Cancer. 2012;19(3):321-31.


    Marcus DM, Goodman M, Jani AB, Osunkoya AO, Rossi PJ. A comprehensive review of incidence and survival in patients with rare histological variants of prostate cancer in the United States from 1973 to 2008. Prostate Cancer Prostatic Dis. 2012;15(3):283-8.


    Goodman M, Ward KC, Osunkoya AO, Datta MW, Luthringer D, Young AN, Marks K, Cohen V, Kennedy JC, Haber MJ, Amin MB. Frequency and determinants of disagreement and error in gleason scores: A population-based study of prostate cancer. Prostate. 2012;72(13):1389-98.  


    Lue HW, Yang X, Wang R, Qian W, Xu RZ, Lyles R, Osunkoya AO, Zhou BP, Vessella RL, Zayzafoon M, Liu ZR, Zhau HE, Chung LW. LIV-1 promotes prostate cancer epithelial-to-mesenchymal transition and metastasis through HB-EGF shedding and EGFR-mediated ERK signaling. PLoS One. 2011;6(11):e27720.  


    Duran C, Qu Z, Osunkoya AO, Cui Y, Hartzell HC. ANOs 3-7 in the anoctamin/Tmem16 Cl- channel family are intracellular proteins. Am J Physiol Cell Physiol. 2012;302(3):C482-93.


    Wang J, Shehata BM, Langness SM, Davis GK, Cheng L, Osunkoya AO. Clear cell, papillary and chromophobe renal cell carcinoma in patients younger than 20 years old: A clinicopathologic study with follow-up. J Pediatr Urol. 2012; 8(5):531-534.


    Oliva IV, Smith SL, Chen Z, Osunkoya AO. Urothelial carcinoma of the bladder with transmural and direct prostatic stromal invasion: does extent of stromal invasion significantly impact patient outcome? Hum Pathol. 2011;42(1):51-6.


    Ali S, Yin-Goen Q, Johnson TV, Han W, Johnson NA, Harris WB, Marshall FF, Young AN, Master VA, Osunkoya AO. Expression of C-reactive protein and cyclooxygenase enzyme-2 in clear cell renal cell carcinoma: correlation with pathological parameters in 110 patients. Tumour Biol. 2011;32(2):375-80.


    Lim MG, Adsay NV, Grignon DJ, Osunkoya AO. E-cadherin expression in plasmacytoid, signet ring cell and micropapillary variants of urothelialcarcinoma: comparison with usual-type high-grade urothelial carcinoma. Mod Pathol. 2011;24(2):241-7.


    Edgerton N, Sirintrapun SJ, Munoz M, Chen Z, Osunkoya AO. Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 24 cases. Int J Urol. 2011;18(1):49-54.


    Chastain EC, Oliva IV, Osunkoya AO. Utility of p63 and high molecular weight cytokeratin in the distinction between urothelial carcinoma with prostatic stromal invasion and urothelial carcinoma with colonisation of prostatic ducts and acini. Pathology. 2012;44(3):199-203.


    Zhang S, Wang X, Osunkoya AO, Iqbal S, Wang Y, Chen Z, Müller S, Chen Z, Josson S, Coleman IM, Nelson PS, Wang YA, Wang R, Shin DM, Marshall FF, Kucuk O, Chung LW, Zhau HE, Wu D. EPLIN downregulation promotes epithelial-mesenchymaltransition in prostate cancer cells and correlates with clinical lymph node metastasis. Oncogene. 2011


    Johnson TV, Ali S, Abbasi A, Kucuk O, Harris WB, Ogan K, Pattaras J, Nieh PT, Marshall FF, Osunkoya AO, Master VA. Intratumor C-reactive protein as a biomarker of prognosis in localized renal cell carcinoma. J Urol. 2011;186(4):1213-7.


    Williamson SR, Zhang S, Yao JL, Huang J, Lopez-Beltran A, Shen S, Osunkoya AO, MacLennan GT, Montironi R, Cheng L. ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. Mod Pathol. 2011;24(8):1120-7.


    Long Q, Johnson BA, Osunkoya AO, Lai YH, Zhou W, Abramovitz M, Xia M, Bouzyk MB, Nam RK, Sugar L, Stanimirovic A, Williams DJ, Leyland-Jones BR, Seth AK, Petros JA, Moreno CS. Protein-coding and microRNA biomarkers of recurrence of prostate cancer following radical prostatectomy. Am J Pathol. 2011;179(1):46-54


    Dowden EE, Osunkoya AO, Baumgarten DA. Localized cystic disease of the kidney: an unusual entity that can mimic a cystic neoplasm. Am J Kidney Dis. 2010;55(3):609-13.


    Moses KA, Oliva IV, Osunkoya AO, Carney KJ. An unusual presentation of a mixed epithelial and stromal tumor in an elderly male. ScientificWorldJournal. 2010;10:1810-3.


    Zhang S, Zhau HE, Osunkoya AO, Iqbal S, Yang X, Fan S, Chen Z, Wang R, Marshall FF, Chung LW, Wu D. Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells. Mol Cancer. 2010;9:9.


    Lee TK, Miyamoto H, Osunkoya AO, Guo CC, Weiss SW, Epstein JI. Smooth muscle neoplasms of the urinary bladder: a clinicopathologic study of 51 cases. Am J Surg Pathol. 2010;34(4):502-9.


    Moses KA, Decaro JJ, Osunkoya AO, Issa MM. Tubulocystic carcinoma of the kidney: a case report of natural history and long-term follow-up. ScientificWorldJournal. 2010;10:586-9.


    Arnold RS, Makarova NV, Osunkoya AO, Suppiah S, Scott TA, Johnson NA, Bhosle SM, Liotta D, Hunter E, Marshall FF, Ly H, Molinaro RJ, Blackwell JL, Petros JA. XMRV infection in patients with prostate cancer: novel serologic assay and correlation with PCR and FISH. Urology. 2010;75(4):755-61.


    Liu J, Lau SK, Varma VA, Moffitt RA, Caldwell M, Liu T, Young AN, Petros JA, Osunkoya AO, Krogstad T, Leyland-Jones B, Wang MD, Nie S. Molecular mapping of tumor heterogeneity on clinical tissue specimens with multiplexed quantum dots. ACS Nano. 2010;4(5):2755-65.


    Johnson TV, Abbasi A, Owen-Smith A, Young AN, Kucuk O, Harris WB, Osunkoya AO, Ogan K, Pattaras J, Nieh PT, Marshall FF, Master VA. Postoperative better than preoperative C-reactive protein at predicting outcome after potentially curative nephrectomy for renal cell carcinoma. Urology. 2010;76(3):766.1-5.


    Johnson TV, Young AN, Osunkoya AO, Master VA. C-reactive protein as a clinically useful biomarker of metastasis of renal cell carcinoma. Mol Diagn Ther. 2010;14(3):191-3.


    Osunkoya AO. Editorial comment to molecular pathology of chromophobe renal cell carcinoma: a review. Int J Urol. 2010;17(7):600-1.


    Healy KA, Carney KJ, Osunkoya AO. Endometrioid adenocarcinoma in the native ureter of a renal transplant patient: case report and review of the literature. ScientificWorldJournal. 2010;10:1714-22.


    Vogt AP, Chen Z, Osunkoya AO. Rete testis invasion by malignant germ cell tumor and/or intratubular germ cell neoplasia: what is the significance of this finding? Hum Pathol. 2010;41(9):1339-44.


    Osunkoya AO, Young AN, Wang W, Netto GJ, Epstein JI. Comparison of Gene Expression Profiles in Tubulocystic Carcinoma and Collecting Duct Carcinoma of the Kidney. Am J Surg Pathol. 2009;33:1103-1106.


    Nigwekar P, Tamboli P, Amin MB, Osunkoya AO, Ben-Dor D, Amin MB. Plasmacytoid urothelial carcinoma: detailed analysis of morphology with clinicopathologic correlation in 17 cases. Am J Surg Pathol. 2009;33(3):417-24.


    Bong GW, Ritenour CW, Osunkoya AO, Smith MT, Keane TE. Evaluation of modern pathological criteria for positive margins in radical prostatectomy specimens and their use for predicting biochemical recurrence. BJU Int. 2009;103(3):327-31.


    Graham TR, Yacoub R, Taliaferro-Smith L, Osunkoya AO, Odero-Marah VA, Liu T, Kimbro KS, Sharma D, O'Regan RM. Reciprocal regulation of ZEB1 and AR in triple negative breast cancer cells. Breast Cancer Res Treat. 2010;123(1):139-47.


    Gupta R, Balzer B, Picken M, Osunkoya AO, Shet T, Alsabeh R, Luthringer D, Paner G, Amin MB. Diagnostic Implications of Transcription Factor Pax 2 Protein & Transmembrane Enzyme Complex Carbonic Anhydrase IX Immunoreactivity in Adult Renal Epithelial Neoplasms. Am J Surg Pathol. 2009;33(2):241-7.


    Lim M, Adsay NV, Grignon DJ, Osunkoya AO. Urothelial Carcinoma with Villoglandular Differentiation: A Study of 14 Cases. Mod Pathol. 2009;22(10):1280-6.


    Schniederjan SD, Osunkoya AO. Lymphoid neoplasms of the urinary tract and male genital organs: a clinicopathological study of 40 cases. Mod Pathol. 2009;22(8):1057-65.


    Arnold RS, Sun CQ, Richards JC, Grigoriev G, Coleman IM, Nelson PS, Hsieh CL, Lee JK, Xu Z, Rogatko A, Osunkoya AO, Zayzafoon M, Chung L, Petros JA. Mitochondrial DNA mutation stimulates prostate cancer growth in bone stromal environment. Prostate. 2009;69(1):1-11.


    Osunkoya AO, Cohen C, Lawson D, Picken MM, Amin MB, Young AN. Claudin-7 and Claudin-8: Immunohistochemical Markers for the Differential Diagnosis of Chromophobe Renal Cell Carcinoma and Oncocytoma. Hum Pathol. 2009;40(2):206-10.


    Osunkoya AO, Yin-Goen Q, Phan JH, Moffitt R, Wang MD, Young AN. Novel Immunohistochemical Biomarkers for Renal Cell Carcinoma Derived from Expression Microarray Data. Hum Pathol. 2009;40(12):1671-8.


    Scharer CD, Laycock N, Osunkoya AO, Logani S, McDonald JF, Benigno BB, Moreno CS. Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells. J Transl Med. 2008 Dec; 6:79.


    Osunkoya AO, Hansel DE, Parwani AV, Ali TZ, Tamas EF, Untawale VG, Kahane H, Epstein JI. The Symphony" Protocol for H&E Staining of Prostatic Adenocarcinoma on Needle Biopsy: A Multicenter Analysis of 120 cases. Pathology. 2008; 40(5):450-456.


    Osunkoya AO, Carter HB, Epstein JI. A clinicopathologic study of preoperative and postoperative findings with minute Gleason 3+3=6 cancer at radical prostatectomy. Urology. 2008;72(3):638-40.


    Yoon GS, Wang W, Osunkoya AO, Lane Z, Partin AW, Epstein JI. Residual tumor potentially left behind after local ablation therapy in prostate adenocarcinoma. J Urol. 2008; 179(6):2203-6.


    Osunkoya AO, Adsay NV, Cohen C, Epstein JI, Smith SL. MUC2 expression in primary mucinous and nonmucinous adenocarcinoma of the prostate: an analysis of 50 cases on radical prostatectomy. Mod Pathol. 2008; 21(7):789-94.


    Graham TR, Zhau HE, Odero-Marah VA, Osunkoya AO, Kimbro KS, Tighiouart M, Liu T, Simons JW, O'Regan RM. Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res. 2008; 68(7):2479-88.


    Landrum LM, Rutledge TL, Osunkoya AO, Mannel R. Uterine leiomyoma with associated pseudo-Meigs syndrome mimicking ovarian carcinoma. JOSMA 2008; 101(2):38-9.


    Osunkoya AO, Nielsen ME, Epstein JI. Prognosis of Mucinous Adenocarcinoma of the Prostate Treated by Radical Prostatectomy: A Study of 47 Cases. Am J Surg Pathol. 2008; 32(3):468-472.


    Osunkoya AO, Hansel DE, Sun X, Netto GJ, Epstein JI. Aberrant Diffuse Expression of p63 in Adenocarcinoma of the Prostate on Needle Biopsy and Radical Prostatectomy: Report of 21 Cases. Am J Surg Pathol. 2008;32(3):461-467.


    Osunkoya AO, Netto GJ, Epstein JI. Colorectal adenocarcinoma involving the prostate: report of 9 cases. Hum Pathol. 2007;38(12):1836-41.


    Tophkhane C, Yang S, Bales W, Archer L, Osunkoya A, Thor AD, Yang X. Bcl-2 overexpression sensitizes MCF-7 cells to genistein by multiple mechanisms. Int J Oncol. 2007;31(4):867-74.


    Osunkoya AO, Epstein JI. Primary mucin-producing urothelial-type adenocarcinoma of prostate: report of 15 cases. Am J Surg Pathol. 2007;31(9):1323-9.


    Kharfan-Dabaja MA, Patel SA, Osunkoya AO, Kojouri K, Kamble R, Yang J, Hashmi M, Ozer H, Selby GB. Expression of the vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukemia: incidence and feasibility of immunohistochemical staining. Clin Lab Haematol. 2006;28(4):254-8.


    Osunkoya AO, Agte SD, Laszik Z. A 67-year-old woman with chronic proteinuria. Focal segmental and global glomerulosclerosis with light microscopic and ultrastructural features consistent with Fabry disease. Arch Pathol Lab Med. 2006;130(6):e93-5.


    Akang E.E.U., Kuti MA, Osunkoya A.O., Malomo A.O., Shokunbi M.T., Amutta S.B.: Pattern of fatal head injuries in Ibadan - a ten year review. Med Sci Law 2002;42(2):160-6.


    Book Chapters -

    Wood H, Angermeier K, Osunkoya AO. Non-Neoplastic and Neoplastic Urethral Disease. The Urinary Tract: A Comprehensive Guide to Patient Diagnosis and Management. Edited by Hansel DE, McKenney JK, eds. Springer 2013


    Osunkoya AO. Prostatic adenocarcinoma, mucinous variant. Uropathology (High Yield Pathology). Edited by Zhou M, Netto GJ, Epstein JI. Elsevier, Philadelphia, 2012.


    Osunkoya AO. Nonprostatic adenocarcinoma involving the prostate. Uropathology (High Yield Pathology). Edited by Zhou M, Netto GJ, Epstein JI. Elsevier, Philadelphia, 2012.


    Osunkoya AO. Paratesticular Rhabdomyosarcoma. Uropathology (High Yield Pathology). Edited by Zhou M, Netto GJ, Epstein JI. Elsevier, Philadelphia, 2012.


    Osunkoya AO. Paratesticular Liposarcoma. Uropathology (High Yield Pathology). Edited by Zhou M, Netto GJ, Epstein JI. Elsevier, Philadelphia, 2012.


    Osunkoya AO. Sclerosing Sertoli cell tumor. Uropathology (High Yield Pathology). Edited by Zhou M, Netto GJ, Epstein JI. Elsevier, Philadelphia, 2012.


    Osunkoya AO. Klinefelter Syndrome. Uropathology (High Yield Pathology). Edited by Zhou M, Netto GJ, Epstein JI. Elsevier, Philadelphia, 2012.


    Osunkoya AO. Multilocular cystic renal cell carcinoma. Uropathology (High Yield Pathology). Edited by Zhou M, Netto GJ, Epstein JI. Elsevier, Philadelphia, 2012.


    Osunkoya AO. Papillary adenoma. Uropathology (High Yield Pathology). Edited by Zhou M, Netto GJ, Epstein JI. Elsevier, Philadelphia, 2012.


    Osunkoya AO. Urothelial carcinoma with villoglandular differentiation. Uropathology (High Yield Pathology). Edited by Zhou M, Netto GJ, Epstein JI. Elsevier, Philadelphia, 2012.


    Osunkoya AO. Urothelial carcinoma with inverted growth pattern. Uropathology (High Yield Pathology). Edited by Zhou M, Netto GJ, Epstein JI. Elsevier, Philadelphia, 2012.


    Osunkoya AO. Malakoplakia. Uropathology (High Yield Pathology). Edited by Zhou M, Netto GJ, Epstein JI. Elsevier, Philadelphia, 2012.


    Osunkoya AO. Penile squamous hyperplasia. Uropathology (High Yield Pathology). Edited by Zhou M, Netto GJ, Epstein JI. Elsevier, Philadelphia, 2012.


    Osunkoya AO. Penile Genital melanocytic macule/lentiginosis. Uropathology (High Yield Pathology). Edited by Zhou M, Netto GJ, Epstein JI. Elsevier, Philadelphia, 2012.


    Osunkoya AO. Leiomyosarcoma of the bladder. Uropathology (High Yield Pathology). Edited by Zhou M, Netto GJ, Epstein JI. Elsevier, Philadelphia, 2012.


    Osunkoya AO. Leiomyoma of the bladder. Uropathology (High Yield Pathology). Edited by Zhou M, Netto GJ, Epstein JI. Elsevier, Philadelphia, 2012.


    Thor AD, Osunkoya AO. Chapter 19 (The Breast) Rubin's Pathology Clinicopathologic Foundations of Medicine. 5th Edition. Published March 2007.


    Other Publications -

    Amin MB, Gupta R, Osunkoya AO, Hes O, Billis A, Bacchi CE, Hansel D, Zhou M, deCastro MG, Moch H, Salles P, Cabrera RA, Gown AM. Carcinoma of Collecting Ducts of Bellini: Analysis of 27 Distinctive Cases of Renal Cell Carcinoma with Aggressive Clinical Behavior. Mod Pathol 2009; 22: 157A.


    Schniederjan SD, Osunkoya AO. Lymphomas of the Genitourinary Tract: A Clinicopathologic Study of 40 Cases. Mod Pathol 2009; 22: 192A.


    Netto GJ, Wang W, Brownlee NA, Osunkoya AO, Hicks J, Sharma R, Albadine R. PAX8 (+)/p63 (-) Immunostaining Pattern in Renal Collecting Duct Carcinoma (CDC): A Useful Immunoprofile in the Differential Diagnosis of CDC vs Urothelial Carcinoma of Upper Urinary Tract. Mod Pathol 2009; 22: 186A.


    Young AN, Yin-Goen Q, Phan JH, Moffitt R, Wang MD, Osunkoya AO. Novel Immunohistochemical Biomarkers for Renal Cell Carcinoma Derived from Expression Microarray Data. Mod Pathol 2009; 22: 202A.


    Moreno CS, Henderson VM, Zhou W, Williams D, Laycock N, Kitayama H, Osunkoya AO. RAP1 Signaling in Prostate Cancer Progression. Mod Pathol 2009; 22: 185A.


    Jani JC, Cohen C, Jehnazeb K, Lawson D, Osunkoya AO. Neuroendocrine, Proliferative and Apoptotic Markers in Prostatic Adenocarcinoma and Small Cell Carcinoma of the Prostate: A Tissue Microarray Analysis of 64 Cases. Mod Pathol 2009; 22: 174A.


    Lotan TL, Osunkoya AO, DeMarzo AM, Netto GJ, Epstein JI. Prostate Adenocarcinomas Aberrantly Expressing p63 Have a Luminal Cell Phenotype. Mod Pathol 2009; 22: 180A.


    Osunkoya AO, Young AN, Wang W, Netto GJ, Epstein JI. Comparison of Gene Expression Profiles in Tubulocystic Carcinoma and Collecting Duct Carcinoma of the Kidney. Mod Pathol 2009; 22: 187A.


    Lim M, Adsay NV, Grignon DJ, Osunkoya AO. Urothelial Carcinoma with Divergent Villoglandular Differentiation: A Study of 14 Cases. Mod Pathol 2009; 22:179A.


    Osunkoya AO, Hansel DE, Sun X, Netto GJ, Epstein JI. Aberrant Diffuse Expression of p63 in Adenocarcinoma of the Prostate on Needle Biopsy and Radical Prostatectomy: Report of 21 cases. Modern Pathology 2008; 21(1S): 174A-175A.


    Yoon GS, Wang W, Osunkoya AO, Lane Z, Epstein JI. Residual Tumor Potentially Left Behind after Local Ablation Therapy in Prostate Adenocarcinoma. Modern Pathology 2008; 21(1S): 192A.


    Young AN, Cohen C, Lawson D, Picken MM, Amin MB, Osunkoya AO. Claudin-7 and Claudin-8: Immunohistochemical Markers for the Differential Diagnosis of Chromophobe Renal Cell Carcinoma and Oncocytoma. Modern Pathology 2008; 21(1S): 192A.


    Smith SL, Adsay NV, Cohen C, Epstein JI, Smith SL. Osunkoya AO. MUC2 Expression in Primary Mucinous and Nonmucinous Adenocarcinoma of the Prostate: An analysis of 50 cases on radical prostatectomy. Modern Pathology 2008; 21(1S): 182A.


    Osunkoya AO, Nielsen ME, Epstein JI. Prognosis of Mucinous Adenocarcinoma of the Prostate Treated by Radical Prostatectomy: A Study of 47 Cases. Modern Pathology 2008; 21(1S): 175A.


    Osunkoya AO, Hansel DE, Parwani AV, Ali TZ, Tamas EF, Untawale VG, Kahane H, Epstein JI. The Symphony" Protocol for H&E Staining of Prostatic Adenocarcinoma on Needle Biopsy: A Multicenter Analysis of 120 cases Modern Pathol 2007; 20(2):167A-168A.


    Osunkoya AO, Netto GJ, Epstein JI. Colorectal Adenocarcinoma Involving the Prostate: Report of 9 Cases. Modern Pathol 2007; 20(2):167A.


    Osunkoya AO, Epstein JI. Primary Mucin-Producing Urothelial-Type Adenocarcinoma of Prostate: Report of 15 Cases. Modern Pathol 2007; 20(2):167A.


    Osunkoya AO, Truong C.D., Laszik Z.G.: TM but not EPCR Expression is Reduced in The Tubulointerstitial Capillaries of Patients with Proliferative and Membranous Lupus Nephritis. Lab Invest. 2006 Jan; 86(1):264A-265A.


    Thor AD, Osunkoya AO. Giant Juvenile Fibroadenoma (GJF). American Society for Breast Disease (ASBD) Expert Advisor commentaries. May 2005.


    Osunkoya AO, Foster T. and Pitha J. Ectopic Meningothelial Hamartoma of the Scalp. J Cutan Pathol 2005: 32: 107A.


    Osunkoya AO, Aronson W, Kern W, Vogel S, Dunn T: Cavernous transformation of the portal vein in a patient with 50% reduction in Protein C, probable polycythemia vera and MTHFR C677T point mutation. Modern Pathol 2003;16(1):6A.